What is the recommended maintenance dose of amiodarone for a pediatric patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maintenance Dose of Amiodarone in Pediatric Patients

The recommended maintenance dose of oral amiodarone in pediatric patients is 5 mg/kg/day, typically administered 5 days per week after an initial loading period. 1, 2

Dosing Algorithm for Pediatric Amiodarone

Loading Phase

  • Oral loading: Administer 10 mg/kg/day for 10 days 1
  • Alternative loading regimens of 10-15 mg/kg/day have been used successfully in some studies 3
  • IV loading (for acute situations): 5 mg/kg bolus followed by 10 mg/kg/day continuous infusion 1, 4

Maintenance Phase

  • Standard maintenance dose: 5-7 mg/kg/day administered 5 days per week 1
  • This intermittent dosing schedule (5 days on, 2 days off) helps minimize cumulative toxicity while maintaining therapeutic efficacy 1
  • Some protocols use continuous daily dosing at 5 mg/kg/day, though the intermittent schedule is more commonly reported 2

Dose Adjustments

  • The maintenance dose should be titrated to the lowest effective level to minimize side effects 2
  • In cases where side effects develop (particularly corneal deposits), dose reduction rather than discontinuation may be sufficient 2
  • Mean effective maintenance doses in clinical practice typically settle around 5 mg/kg/day 2

Critical Monitoring Requirements

Mandatory Surveillance

  • Thyroid function tests: Check quarterly during therapy 1

    • Blood level fluctuations of T3 and T4 occur in 86% of pediatric patients, though most remain within normal ranges 1
    • Therapy discontinuation for thyroid dysfunction occurs in approximately 8-11% of cases 1, 2
  • Holter monitoring: Perform quarterly to assess arrhythmia control and detect bradycardia 1

  • Ophthalmologic examination: Every 6 months to detect corneal deposits 1

    • Corneal deposits occur but rarely impair visual acuity in children 1
  • Chest radiography and echocardiography: Annually to screen for pulmonary fibrosis 1

Common Pitfalls and Adverse Effects

High incidence of side effects (24% in long-term pediatric use) necessitates vigilant monitoring 2:

  • Photosensitivity: Occurs in 22% of children—counsel families about sun protection 1
  • Bradycardia: More pronounced in infants less than 1 year old; reduction in sinus automatism is expected 1
  • AV conduction delays: First-degree AV block may develop; monitor ECG regularly 1
  • Pulmonary toxicity: Rare but serious; any new respiratory symptoms require immediate evaluation 2
  • Thyroid dysfunction: Requires laboratory and clinical monitoring; may necessitate treatment discontinuation in 8% of cases 1

Efficacy Data

Oral amiodarone demonstrates exceptional efficacy in pediatric arrhythmias:

  • Complete effectiveness in 77% of children with oral therapy 1
  • Partial response in 5%, ineffective in only 18% 1
  • Success maintained over mean follow-up of 13 months 1
  • Particularly effective for supraventricular tachycardia associated with Wolff-Parkinson-White syndrome, with 90% of patients becoming asymptomatic within 5 days 3

Special Considerations for Cardiac Arrest

For shock-refractory VF/pulseless VT during cardiac arrest, the dosing differs significantly from maintenance therapy:

  • Bolus dose: 5 mg/kg IV/IO during cardiac arrest 5
  • May repeat up to 2 times for refractory rhythms 5
  • This acute dosing is distinct from chronic maintenance therapy and applies only to resuscitation scenarios 5

Drug Interactions in Pediatric Patients

When initiating amiodarone maintenance therapy, adjust concomitant medications 5:

  • Digoxin: Reduce dose by 30-50% as amiodarone increases digoxin levels 5
  • Monitor for bradycardia when combining with other AV nodal blocking agents 5

Practical Implementation

The typical pediatric maintenance regimen follows this pattern:

  1. Complete 10-day loading at 10 mg/kg/day 1
  2. Transition to 5-7 mg/kg/day for 5 days weekly 1
  3. Assess response at 5 days (most patients become asymptomatic) 3
  4. Continue maintenance dosing with quarterly monitoring 1
  5. Adjust dose downward if side effects emerge, rather than discontinuing immediately 2

The extremely long half-life of amiodarone (15-100 days, average 58 days) means therapeutic effects persist long after dose adjustments, requiring patience when titrating 6, 7

References

Research

[Amiodarone therapy in childhood: efficacy and side effects].

Giornale italiano di cardiologia, 1985

Research

[Amiodarone for long term treatment of arrhythmia in children].

Wiadomosci lekarskie (Warsaw, Poland : 1960), 2001

Research

Pharmacokinetics of intravenous amiodarone in children.

Archives of disease in childhood, 2013

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Administering IV Amiodarone with Bradycardia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Ten years of experience with amiodarone.

American heart journal, 1983

Related Questions

What is the appropriate dosing regimen for amiodarone in a pediatric patient?
What is the recommended dose of amiodarone in pediatric resuscitation?
What is the recommended rate for increasing the amiodarone (antiarrhythmic medication) infusion rate, and can 0.7 mg/min be administered?
What are the adverse effects of Amiodarone (antiarrhythmic medication)?
What is the recommended infusion protocol for Amiodarone (antiarrhythmic medication)?
For how long should permissive hypertension be allowed in older adult patients with Transient Ischemic Attack (TIA) and underlying vascular risk factors such as hypertension, diabetes, and hyperlipidemia?
Does rasburicase require premedication before administration in an adult patient with elevated uric acid levels, potentially undergoing chemotherapy, and screened for G6PD deficiency?
Is having a metallic valve an automatic indication to start vancomycin in a patient with suspected infective endocarditis?
What is the management plan for a patient with a blood test indicating Reticuloendothelial System (RES) dysfunction, considering their age, gender, and medical history?
Can febuxostat (xanthine oxidase inhibitor) be used concurrently with rasburicase (uric acid oxidase) in patients with hyperuricemia (elevated uric acid levels) undergoing chemotherapy and previously screened for glucose-6-phosphate dehydrogenase (G6PD) deficiency?
What is the appropriate management for a patient with a blood test indicating a diagnosis of Relative Energy Deficiency in Sport (RED-S), likely due to intense athletic training and potential disordered eating or body image issues?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.